Breaking News: BLUE – Market Insights, Analysis & Latest Updates

BLUE
NOVN
PFE
VRTX

Why gene therapy for sickle cell is slow to catch on with patients

Zoe Davis, a sickle cell patient, hesitates to try new gene therapies due to their novelty and costs. Many patients face similar challenges, impacting treatment uptake.

investing.com • 28/09/2024 - 10:22 AM

AGIO
BLUE
FULC
PFE
VRTX

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's withdrawal of sickle cell treatment Oxbryta due to death risks may accelerate trials for rival drugs and leaves many patients relying on older treatments like hydroxyurea.

investing.com • 26/09/2024 - 15:39 PM

Greed and Fear Index

Note: The data is for reference only.

Fear

Why gene therapy for sickle cell is slow to catch on with patients

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Currency